2 Min Read
![Plant on the Road to Remediation as Celltrion Resubmits Biosimilars Plant on the Road to Remediation as Celltrion Resubmits Biosimilars](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt277a1b89a5ce25f8/658aeffcc4ff89040a3d7f1d/korea-flag.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
Celltrion has completed the resubmission of versions of Herceptin and Rituxan to the US FDA after receiving complete response letters for the two biosimilars in April.
Earlier this year, the US Food and Drug Administration (FDA) issued complete response letters (CRLs) to South Korean drugmaker Celltrion for its rituximab and trastuzumab biosimilars. The letters cited a warning letter